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Penile squamous cell carcinoma (PSCC) is rare; hence little is known about its 
aetiology and pathogenesis. Two challenges exist in the clinical management of 
PSCC patients. Firstly, finding a non-invasive method to aid the detection of occult 
lymph node metastasis to improve patient selection for inguinal lymphadenectomy. 
Secondly, the development of novel treatment strategies for those with advanced 
PSCC, as current treatment options are limited.  
A high prevalence of copy number gain in the chromosome 3q arm has been 
identified and linked to poor cancer-specific and disease-free survival in PSCC. 
Within this region lies the PIK3CA oncogene, which is mutated/amplified/gained and 
results in the activation of the PI3K-AKT-mTOR pathway. PIK3CA copy number gain 
has not been fully investigated in PSCC and it has the potential to be a driver gene in 
penile carcinogenesis and the PI3K-AKT-mTOR pathway presents an opportunity for 
targeted therapeutics in PSCC.  
I demonstrated an increasing frequency of PIK3CA copy number gain with evolving 
PSCC disease state (penile intraepithelial neoplasia (10/58; 17%), primary PSCC 
(83/199; 42%), advanced primary PSCC (20/26; 77%); p<0.0001) with few PIK3CA 
mutations in PSCC (3/51; 6%). PIK3CA copy number gain correlated with more 
aggressive PSCC subtypes (p=0.0028), higher tumour grade (p<0.0001) and stage 
(p=0.0043) and thus could be used as a marker of high-risk disease.  However, it 
shows no significant association with lymph node metastasis or prognostic value for 
cancer-specific survival in PSCC.  
Overall, I confirmed that the PI3K-AKT-mTOR pathway activity is primarily involved in 
early penile carcinogenesis and based on these findings the therapeutic targeting of 
this pathway in those with advanced PSCC disease is unlikely to produce significant 
clinical benefit. Future studies will need to focus on the identification of new clinically 
relevant candidate genes and signalling pathways, which offer prognostic value and 




                                                                                                          	






aCGH  Array Comparative Genomic Hybridisation 
BAC  Bacterial Artificial Chromosome 
BCIP  5-bromo-4-chloro-3-indolyl-phosphate 
bp  Base Pair 
BSA   Bovine Serum Albumin 
cDNA  Complementary Deoxyribonucleic Acid 
CIN  Chromosomal Instability 
CSCC  Cervical Squamous Cell Carcinoma 
CSS  Cancer-Specific Survival 
CT  Computed Tomography 
CT  Cycle Threshold 
DIG  Digoxigenin 
DNA  Deoxyribonucleic Acid 
EGFR  Epidermal Growth Factor Receptor 
FISH  Fluorescence In-Situ Hybridisation 
FFPE  Formalin-Fixed Paraffin Embedded 
H&E  Haematoxylin and Eosin 
HISCC  Human Papilloma Virus Induced Squamous Cell Carcinoma 
HNSCC  Head and Neck Squamous Cell Carcinoma 
HrHPV  High Risk Human Papilloma Virus 
HPV  Human Papilloma Virus 
HRP   Horseradish Peroxidase 
                                                                                                          	




IHC  Immunohistochemistry 
IRS1  Insulin Receptor Substrate 1 
Kb  Kilobase 
LB  Lysogeny Broth 
LrHPV  Low Risk Human Papilloma Virus 
M-MLVRT(H-) Moloney Murine Leukaemia Virus Release Transcriptase, RNAse H 
   Minus Point Mutant  
MIN  Microsatellite Instability 
mTORC1 mTOR/raptor complex 
mTORC2 mTOR/rictor complex 
NBT  Nitro Blue Tetrazolium 
OSCC  Oesophageal Squamous Cell Carcinoma 
PAGE  Polyacrylamide Gel Electrophoresis 
PBS  Phosphate Buffered Saline 
PeIN  Penile Intraepithelial Neoplasia 
PET  Positron Emission Tomography 
PI3K  Phosphatidylinositol 3-Kinase 
PI3Kα  Phosphatidylinositol 3-Kinase p110α Protein 
PIK3CA  Phosphatidylinositol-4,5-bisphosphate 3-Kinase Catalytic Subunit  
   Alpha 
PIP2  Phosphatidylinositol (4,5) Bisphosphate or Phosphatidylinositol (3,4) 
   Bisphosphate 
PIP3  Phosphatidylinositol (3,4,5) Trisphosphate 
PCR  Polymerase Chain Reaction 
pRB  Retinoblastoma 
                                                                                                          	




PSCC  Penile Squamous Cell Carcinoma 
PTEN  Phosphatase and Tensin Homolog 
PVDF  Polyvinvlidene Difluoride 
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RQ  Relative Quantification 
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1.1.1 Definition, Epidemiology and the Hallmarks of Cancer 
Cancer is the nomenclature given to a collection of diseases, which have uncontrolled 
cellular growth and can invade and metastasize to distant sites of the body. It is a 
major cause of morbidity and mortality in Europe with 3.45 million and 1.75 million 
new cases and deaths from cancer, respectively, each year (1, 2). In the UK, there 
are 352,197 and 161,823, new cases and death from cancer a year and these figures 
are expected to increase due to an ageing and ever growing population (3). 
The evolution of cancer is a complex and multi-step process, which involves the 
successive accumulation of genetic alterations such as mutations that confer a 
selective growth advantage that drives the transformation of normal cells into 
malignant cancers (4). Despite the existence of various types of cancers, it is widely 
accepted that for normal cells to evolve progressively into a neoplastic state, they 
must acquire some or all of a succession of specific biological hallmark capabilities 
which include: (i) sustaining proliferative signals, (ii) resisting cellular apoptosis, (iii) 
enabling replicative immortality, (iv) resistance to growth inhibitory signals, (v) 
immune system evasion, (vi) induction of angiogenesis, (vii) tissue invasion and 
metastasis, (viii) reprogramming of cellular energy metabolism, (ix) tumour-promoting 
inflammation and (x) genomic instability and mutations (5, 6). (Figure 1.1)
                                                                                                          	





Figure 1.1 Cancer Hallmarks. Adapted from Hanahan et al. (5) 
 
The molecular bases of each of these essential biological hallmarks are common to 
most if not all malignancies and each capability represents a potential target for 
mechanistic-based cancer therapeutics.  
1.1.2 Genomic Instability in Cancer 
Genomic instability can be described as the increased rate of spontaneous genetic 
alterations that impairs normal cellular biological mechanisms that repair, replicate 
and ensure the accurate segregation of the genome during cell division. Thus 
promoting the acquisition of further DNA alterations, clonal evolution and tumour 
heterogeneity (4, 7, 8). Genomic instability, which is an almost universal feature of 
cancer cells, occurs at two distinct levels: nucleotide (microsatellite instability) and 
chromosomal (chromosomal instability) (9).  
Microsatellites, also known as short tandem repeats, are simple repeated short motifs 
usually of one to six base pairs long, which are scattered throughout the genome and 
                                                                                                          	




are particularly prone to DNA replication errors (10, 11). Microsatellite instability (MIN) 
manifests from defects in the DNA mismatch repair genes (such as the MLH1, MSH2, 
PMS2 genes among others), which causes random deletions, insertions and 
expansion of microsatellites and leads to a hypermutable phenotype (9, 11). This 
facilitates cellular malignant transformation via accumulation of mutations leading to 
activation and inactivation of key oncogenes and tumour suppressor genes, 
respectively, which have fundamental cellular functions (10, 12). MIN is a 
characteristic feature of a number of cancers, such as gastric and colorectal cancer, 
the latter of which, is where it was first described and has been extensively studied 
(13-15).  
Among the inherent types of genomic instability, chromosomal instability (CIN) is the 
most common form. CIN is characterised by the high rate of gains and/or loss of 
whole chromosomes or chromosomal segments and hence structural and numerical 
chromosomal alterations and an abnormal karyotype (16, 17). Numerical CIN results 
from chromosome segregation defects that are caused by mechanisms such as 
multipolar spindles and centrosome amplification for example (18). Whilst structural 
CIN results from chromosome breakage and rearrangement due to defects in cell 
cycle checkpoints and the loss of telomeres integrity among other mechanisms (17, 
19). These alterations lead to aneuploidy, translocations, amplifications, insertions, 
inversions and deletions and thus karyotypic instability and the increased probability 
of cellular dedifferentiation, malignancy and survival in stressful microenvironments. 
The human papillomavirus (HPV) is well known to interfere with these aforementioned 
processes, causing CIN and tumour formation in infected epithelial cells (4, 18). 
It is still unclear whether genomic instability is just an incidental by-product of the 
microevolution of the tumour or whether it is the primary driving force of 
tumourigenesis occurring early, late or throughout this on going process. However, it 
has been proposed that the different cancers follow alternative pathways of initiation 
and hence the role of genomic instability in carcinogenesis may vary depending on 
the tumour type (17, 20). 
                                                                                                          	




1.2 Penile Cancer 
1.2.1 Epidemiology 
Penile cancer is a rare disease in Europe and North America, representing 
approximately 0.5% of all male malignancies (21). The incidence of PSCC in Europe 
varies geographically ranging from 0.45 – 1.7 per 100,000 population (22), with 600 
new cases diagnosed each year in the UK (23). This malignancy occurs 
predominantly in elderly men, with an increasing incidence with age, with the highest 
rate being between 50 and 70 years (24). 
The clinical course of penile cancer is interesting with two distinct groups of patients 
seen. The first is a large patient cohort with a high cure rate (80%) and excellent long-
term survival as their disease is organ-confined with no or minimal regional lymph 
node involvement (24, 25). The second is a smaller patient cohort with highly 
aggressive disease with significant propensity to metastasise and poor prognosis (25, 
26). Management of the latter group with aggressive and advanced tumours still 
remains difficult as most are chemo/radio-resistant with limited treatment options 
available (27). 
One of the main challenges in penile cancer remains patient selection for radical 
inguinal lymphadenectomy, which can cause significant morbidity, in those with 
clinically node negative disease as around 25% will have occult metastasis. Standard 
clinico-pathological parameters are well established and the mainstay in guiding 
current patient management and prognosis. The most important of these remains the 
presence and extent of lymph node metastases, which is a key determinant of long-
term patient survival in penile cancer (26, 27).  
Several molecular markers such as squamous cell carcinoma antigen and Ki-67 have 
been evaluated, in hope of finding a potentially useful adjunct to conventional 
pathological variables. Unfortunately, the clinical application of these markers remains 
limited (28-30). Nonetheless, novel molecular markers are required not only for 
prognostication and the accurate determination of lymph node status but also to serve 
as chemotherapeutic targets and aid in tailoring therapeutic treatments to individual 
patients (30).  
 
                                                                                                          	




1.2.2 Risk Factors and Pathology  
Several risk factors have been identified which are thought to contribute to the 
development of penile cancer. One of the most important and extensively studied is 
infection with HPV. Around 33% of all penile cancer cases are associated with HPV 
(31), similar to vulvar (32) and head and neck cancers (33, 34). Other risk factors 
include phimosis, chronic inflammation, poor penile hygiene, penile trauma and 
smoking (22, 35). 
Penile tumours originate most commonly from the epithelium of the penile glans, 
inner prepuce (foreskin), and coronal sulcus and less commonly on the penile shaft 
(36). They may arise from the malignant transformation of precursor lesions - penile 
intraepithelial neoplasia (PeIN), the rate at which this occurs is not well defined, but is 
thought to arise in approximately 30% of cases, if left untreated (37, 38) (Figure 1.2).   
 
 
Figure 1.2 Penile Anatomy. Adapted from Medscape (39)  
 
Squamous cell carcinoma accounts for around 95% of all malignant disease of the 
penis (40). The remaining 5% comprise of various rare tumour entities from clear cell 
and basal cell carcinomas to melanomas and sarcomas among others (41). Despite 
penile squamous cell carcinoma (PSCC) being the most common penile neoplasm, 
various distinct histological subtypes (including those with a mixed histological 
background) exist each with histotype specific associations with human papilloma 
virus and clinical aggressiveness (41-45). (Table 1.1) 
                                                                                                          	
















Usual 48-65 24-59 28-39 Intermediate 
Basaloid 4-10 70-100 50-100 Poor 
Warty 7-10 22-78 17-18 Good 
Verrucous 3-8 0-23 Nil Excellent 
Papillary 5-15 8-15 12 Good 
Data from the following references: (34, 43, 45) 
 
1.2.3 Diagnoses and Staging  
To ensure the appropriate treatment selection for each patient careful diagnosis and 
staging of the malignancy is paramount. Clinical examination is important as it may 
identify the primary lesion, which may present as a localised mass, ulcer or 
inflammatory lesion (27).  To accurately diagnose penile cancer, biopsy of the lesion 
is required for histopathological confirmation.   
Determination of lymph node involvement in penile cancer is a crucial step for 
staging, treatment and prognosis, which is carried out by careful physical examination 
of each groin (46). In patients with non-palpable inguinal nodes with intermediate and 
high-risk disease, invasive nodal staging with bilateral dynamic sentinel lymph node 
biopsy is recommended. Whilst those with low risk disease are put under a 
surveillance program (24, 47-49). In those patients with confirmed lymph node 
metastasis, radiological staging for distant metastasis and systemic disease is 
required which is carried out with abdomino-pelvic computed tomography (CT) or 
positron emission tomography/CT (PET/CT) scan, chest radiography and a bone 
scan if indicated (50, 51). 
Staging of penile cancer is essential for the determination of patient treatment and 
prognosis and is linked to patient survival and disease progression (52). Penile
                                                                                                          	




cancer can be staged pathologically and/or clinically (24). Both staging methods 
follow the TNM classification, were the extent of the primary tumour (T category) and 
nodal involvement (N category) is taken into account, as is the presence or absence 
of distant metastasis (M category). Tumour grade, which is based on the degree of 
cellular differentiation, is also a key part of the pathological TNM classification due to 
its prognostic relevance (53, 54). Table 1.2 and 1.3 - both adapted from (24). 
 
Table 1.2 Penile Cancer TNM Clinical Staging Classification  
Penile Cancer TNM Clinical Staging 
T - Primary Tumour TX S Primary tumour cannot be assessed 
 T0 S No evidence of primary tumour 
 Tis S Carcinoma in-situ 
 Ta S Non-invasive carcinoma 
 T1 S Tumour invades sub-epithelial connective tissue 
 T2 S Tumour invades corpus spongiosum and/or  
    corpora cavernosa 
 T3 S Tumour invades urethra 
 T4 T Tumour invades other adjacent structures 
 




   Regional lymph nodes cannot be assessed 
 N0 S No palpable or visibly enlarged inguinal node 
 N1 S Palpable mobile unilateral inguinal node 
 N2 X Palpable mobile multiple unilateral or bilateral  
    inguinal nodes 
 N3 X Fixed inguinal nodal mass or pelvic node(s) 
 
M- Distant Metastasis M0 S No distant metastasis 
 M1    Distant metastasis 
   
                                                                                                          	




Table 1.3 Penile Cancer TNM Histopathological Staging Classification  
Penile Cancer TNM Histopathological Staging 
T - Primary Tumour pTX S Primary tumour cannot be assessed 
 pT0 S No evidence of primary tumour 
 pTis S Carcinoma in-situ 
 pTa S Non-invasive carcinoma 
 pT1 S Tumour invades sub-epithelial connective tissue 
 pT2 S Tumour invades corpus spongiosum and/or  
    corpora cavernosa 
 pT3 S Tumour invades urethra 
 pT4 T Tumour invades other adjacent structures 
 




  Regional lymph nodes cannot be assessed 
 pN0 S No regional lymph node metastasis 
 pN1 S Intranodal metastasis in a single inguinal node 
 pN2 X Metastasis in multiple unilateral or bilateral  
    inguinal nodes 
 pN3 X Metastasis in pelvic nodes(s) or extranodal  
    extension of any regional lymph node 
 
M- Distant Metastasis pM0 S No distant metastasis 
 pM1   Distant metastasis 
   
G - Tumour Grade GX X Grade of differentiation cannot be assessed 
 G1 S Well differentiated 
 G2   Moderately differentiated 
 G3   Poorly differentiated 
 G4   Undifferentiated 
   
                                                                                                          	




1.2.4 Clinical Management 
The choice of definitive treatment of the primary tumour depends on the grade and 
stage of the primary lesion, local clinical practice and the physical wellbeing of the 
patient and their wishes.  However, the fundamental goal remains to achieve 
complete tumour eradication with the implementation of penile preservation treatment 
whenever possible (24, 46).  
Surgical intervention remains the most common method for treatment with penile 
sparing surgeries such as glans resurfacing and glansectomy with reconstruction 
preferred due to good oncological outcomes and cosmetic results (55, 56). Treatment 
with topical chemotherapy such as 5-flurouracil, laser ablation and radiotherapy still 
remain alternatives in certain penile cases for example in those with early stage non-
invasive disease, small tumours or in those unfit for surgical intervention (37, 57-59). 
The management of the regional lymph nodes is fundamental in penile cancer and 
treatment of confirmed inguinal lymph node metastasis is with radical inguinal 
lymphadenectomy (60). Pelvic lymphadenectomy is indicated in only those with pelvic 
lymph nodes seen on radiological imaging, evidence of extra-capsular nodal 
metastasis or when more than two inguinal lymph nodes are positive, due to the high 
risk of pelvic lymph node metastasis between 23 - 56% (61-63).  
Radiotherapy is only used for palliation in those with advanced disease and may 
improve loco-regional control in patients with extensive metastases and/or extra-
nodal spread (24). Chemotherapy for penile cancer is used for the treatment and 
palliation of advanced or metastatic disease, as well as in the neo-adjuvant and 
adjuvant setting for locally invasive or fixed inguinal lymph nodes. But due to the rarity 
of this tumour, there is a paucity of prospective randomised clinical trial data resulting 
in multiple small heterogeneous studies being published, making evidence-based 
recommendations in current guidelines difficult (64).  
                                                                                                          	




Current first-line chemotherapy for penile cancer consists of a taxane, cisplatin, and 
5-fluouracil or ifosfamide (TPF or TIP) as these regimes demonstrated good objective 
tumoural response (65-68), but significant toxicity has been noted with TPF treatment 
(69, 70). 
However, penile cancer is inherently radiotherapy and chemotherapy resistant. There 
are limited second-line chemotherapeutic options for the systemic treatment of penile 
cancer, once first-line therapy eventually fails (64). A few targeted therapeutic agents 
have been used as second-line treatment for patients with refractory disease with 
modest results. These include anti-epidermal growth factor receptor (EGFR) 
monoclonal antibodies such as cetuximab and panitumumab (71-73), and receptor 
tyrosine kinase (RTK) inhibitors such as sorafinib and sunitinib (74). These targeted 
therapeutics bind to the extracellular domain of the EGFR and multiple RTKs, 
respectively. Consequently, they block the receptor-dependent activation of 
downstream signal transduction, hence providing multiple anti-tumour effects from 
inhibition of angiogenesis to cell cycle arrest and induction of apoptosis (75, 76). 
 
1.3 Molecular Pathogenesis of Penile Cancer 
The molecular mechanisms underlying penile carcinogenesis are still largely unknown 
and seldom studied. This is largely due to the rarity of the disease and hence the 
small number of cases and limited tissue material available for molecular and 
translational research.  
However, the establishment of supra-regional penile cancer networks with 
centralisation of penile care services in the UK and organisation of international and 
national research collaborations will undoubtedly improve patient management and 
our understanding of this disease (77, 78). A greater understanding of the molecular 
mechanisms of penile carcinogenesis will lead to identification of biomarkers and 
novel treatment strategies in penile cancer.  
Our fundamental understanding of the underlying aetiology of penile cancer is in 
recognition of its heterogeneity and two distinct molecular pathways of 
carcinogenesis: the HPV and non-HPV mediated pathways (79). 
                                                                                                          	




1.3.1 HPV Dependent Penile Carcinogenesis 
HPVs are non-enveloped small circular double-stranded DNA viruses. There are 
more than 100 known variants of HPV of which around 40 are known to infect the 
anogenital mucosa (80). These mucosal HPVs are classified in to high- and low-risk 
groups, which reflect the malignant potential of the lesion they cause to progress into 
invasive cancer such as cervical, anal, vulvar or penile cancer (81, 82). (Table 1.4) 
 
Table 1.4 Oncogenic Potential of HPV Subtypes 




16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 
26, 53, 66, 68, 73, 82 
6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 
Adapted from Munoz et al. (81) 
 
High-risk HPVs (hrHPV) are associated with around 33% of all penile cancer cases, 
with HPV 16 the most prevalent subtype (34). Low-risk HPV (lrHPV) such as HPV 6 
and 11, are more commonly associated with benign lesions such as condylomata 
acuminate (41) and respiratory papillomas (83). These lrHPV variants are not thought 
to be actively involved in carcinogenesis, as it has been shown that their oncoproteins 
do not cause significant dysregulation of RB and p53 tumour suppressor pathway, 
leading to minimal p16INK4A upregulation (84). However, these lrHPV variants are 
commonly found in PSCC with HPV 6 the second most common HPV subtype found 
in this tumour (3.7%) (31). 
HPV virions are thought to gain access to and infect the basal cells of the epithelial 
mucosa via micro-abrasions and specific receptors such as heparan sulphate 
proteoglycans and α6 integrins (85). Persistent epithelial HPV infection and integration 
of HPV DNA into the host cell genome, leads to a transformed malignant phenotype 
(Figure 1.3) (82). This results in genomic instability and overexpression of high-risk 
viral oncoproteins E6 and E7 that exert a dysregulating effect on cell cycle control that 
is key to the maintenance of the cancer phenotype (80, 86).  
                                                                                                          	





Figure 1.3 HPV Infection of the Basal Cells of the Epithelial Mucosa. HPV virions gain access to and infect the 
basal cells of the epithelial mucosa via micro-abrasions and specific receptors. Persistent infection with hrHPV can 
lead to dysplasia (PeIN) then to invasive squamous cell carcinoma, which is poorly differentiated. Progression is rare 
and a slow process, with many lesions regressing spontaneously. Adapted from Hellner et al. (82).  
 
The major biological functions of the high-risk viral oncoproteins E6 and E7, lie in their 
inactivation of the tumour suppressors proteins, p53 and retinoblastoma (pRB), 
respectively. High-risk HPV E7 oncoprotein associates with and inactivates pRB via 
binding and disruption of the pRB-E2F complex and/or inducing proteasome-
mediated degradation of pRB. This releases the transcription factor E2F to activate 
genes involved in DNA synthesis and results in uncontrolled cell cycle progression 
(87). This process leads to the overexpression of p16INK4A, due to the disruption of the 
negative feedback loop between p16INK4KA and pRB (34, 88). This allows p16INK4KA 
overexpression to be used as a surrogate marker of transcriptionally active HPV 
infection in penile caner, which has been shown by multiple groups (89-91).  
HrHPV E6 oncoprotein targets the p53 tumour suppressor protein for proteasome-
mediated degradation by forming a tripartite complex with p53 and the cellular 
ubiquitin ligase E6-associated protein. This leads to prevention of DNA repair, growth 
arrest and apoptosis and predisposes the infected cell to accumulation of secondary 
genetic events such as mutations that eventually lead to cancer (92).  (Figure 1.4) 
 
                                                                                                          	





Figure 1.4 Cell-Cycle Dysregulation caused by HrHPV Infection. (A) In normal uninfected epithelium, growth 
factors activate cyclinD/Cdk4/6 complexes, which lead to pRB phosphorylation and release of the transcription factor 
E2F, which drives the expression of proteins, needed for S-phase progression. p16INK4A regulates the levels of active 
cyclinD/Cdk, by binding Cdk4 and thus preventing the phosphorylation of pRB leading to cell cycle arrest. This 
provides a negative feedback mechanism that regulates the levels of cyclin E and PCNA. p14ARF regulates MDM 
ubiquitin ligase, which in turn regulates p53 levels (B) HPV oncoprotein E7 binds and degrades pRB and facilitates 
E2F mediated DNA transcription. Although, p16INK4A levels rise, normal feedback is by-passed due to cyclin/Cdk 
independent cell-cycle progression. The rise in p16INK4A leads to a concomitant rise in p14ARF, which leads to inhibition 
of MDM function, and increase in p53. This is countered by the viral oncoprotein E6 that associates with E6-
associated protein ubiquitin ligase and stimulates the degradation of p53 preventing growth arrest and/or apoptosis. 
Adapted from Doobar et al. (93) 
 
Previous studies have also noted other important carcinogenic functions of the 
oncoproteins E6 and E7. One example includes the HPV E6 oncoprotein mediated 
activation of telomerase via c-myc induced hTERT expression (80) (94) and 
degradation of the NFX1-91, a repressor for the hTERT promoter (95) that leads to 
cellular immortalisation. Both E6 and E7 oncoproteins can induce genomic instability 
by mechanisms such as aberrant centrosome synthesis and subversion of mitotic 
checkpoints causing a higher incidence of mutations and structural chromosome 




                                                                                                          	




1.3.2 HPV Independent Penile Carcinogenesis 
The genetic mechanisms behind HPV negative penile carcinogenesis are less well 
understood.  Two studies analysed the genomic changes in penile cancer by array 
comparative genomic hybridisation (aCGH) methods. La-Touche et al. (97) performed 
the largest aCGH thus far on 64 PSCC cases. They reported recurrent gains in 
chromosomes 1p13.3-q44 (88%), 3p12.3-q29 (86%), 5p15.33-p11 (67%) and 8p12-
q24.3 (84%) and losses in chromosomes 2q33- q37.3 (86%) and 11q12.2-q25 (81%). 
Similar patterns of genetic aberrations were found between HPV positive and 
negative PSCC cases, which they suggested provide evidence that similar molecular 
pathways are targeted by HPV positive and negative PSCC and both may utilise a 
final common pathogenetic pathway. 
Busso-Lopes et al. (98) in 46 PSCC cases discovered, significantly lower cancer-
specific and disease-free survival in cases with losses of 3p21.1-p14.3 (p=0.0006 and 
p=0.023, respectively) and gains of 3q25.31-q29 (p=0.017 and p=0.042, respectively). 
These regions may harbour potential prognostic biomarkers and future therapeutic 
targets in penile cancer. They also identified 19 specific genomic alterations which 
were more common in HPV positive PSCC cases and nine of which are breakpoints 
previously described as associated with HPV integration sites in cervical carcinoma 
(e.g. loss of 5q31.1 and gain of 19q13.32) (99). Thus supporting the hypothesis of two 
distinct PSCC aetiologies: one dependent and the other independent of HPV 
infection. 
More recently, Feber et al. (100) carried out the most comprehensive analysis to date 
of the somatic mutational landscape of PSCC via whole exome sequencing. They 
found few recurrent somatic mutations in 27 PSCC cases with only 137 (17%) 
recurrent events out of 810 mutated genes identified, with the most common in TP53 
(19%) and CSN1 (17%). Interestingly, despite not finding any significant association 
between mutational burden and HPV status, on stratification for HPV viral load, they 
found high viral load tumours, which they defined as >1 HPV copy/cell via qPCR, had 
a significantly (p<0.05) lower mutational load when compared to HPV negative 
tumours.  
Chronic inflammation is a known risk factor for penile cancer and a key mediator of 
inflammation, cyclooxygenase-2, is strongly expressed in PeIN, invasive PSCC and 
                                                                                                          	




lymph node metastasis, but not in normal tissue (101, 102). The overexpression of 
cyclooxygenase-2 leads to overproduction of prostaglandins and thromboxans, which  
play a pivotal role in proliferation, invasion and angiogenesis (103). 
Dysregulation of major tumour suppressor pathways, p16INK4A/cyclin D/RB and 
p14ARF/MDM2/p53 pathways has been found to occur also by HPV independent 
mechanisms promoting penile carcinogenesis. The p16INK4A gene often inactivated by 
loss of heterozygosity and silencing via DNA methylation with loss of p16INK4A 
immunoexpression has been significantly associated with lymph node metastasis and 
disease recurrence (104, 105). In addition, overexpression of BMI-1 polycomb gene, 
which results in down-regulation of p16INK4A and p14ARF, has been found in penile 
cancer (88). (Figure 1.5) 
Allelic loss and mutations of TP53, p14ARF mutation and methylation, and 
overexpression of MDM2, which is a negative regulator of TP53, have also been 
shown in penile cancer (104, 106, 107) (Figure 1.5). Mutation of TP53 can also lead 
to increased expression of an inactive p53 mutant protein (90%) or absent p53 
protein expression (10%) (40). Multiple studies have investigated p53 
immunoexpression in penile cancer with varying detection rates from 41.5% to 89% 
cited (34). In addition, there is recognition in the literature of an association between 





                                                                                                          	





Figure 1.5 HPV- and Non-HPV mediated Dysregulation of Major Tumour Suppressor Pathways, RB and p53. 
Both the HPV dependent and HPV independent pathways lead to dysregulated cell cycle control and evasion of 
apoptosis through disruption of the p16INK4A/cyclin D/RB and p14ARF/MDM2/p53 pathways. HrHPV mediated 
dysregulation of these pathways is a result of the actions of its hrHPV oncoproteins E7 and E6. The E7 oncoprotein 
binds and degrades RB thus facilitating cell cycle progression and the E6 oncoprotein stimulates the degradation of 
p53 preventing DNA repair growth arrest and/or apoptosis. Non-HPV mediated disruption of these two key pathways 
include p16 promoter methylation which causes transcriptional silencing of the p16 tumour suppressor gene, p14 and 
p53 mutations and also overexpression of BMI-1 which is an oncogene that represses the tumour suppressor genes, 
p16 and p14.  Adapted from Bleeker et al. (41) 
 
Ki-67 is a non-histone nuclear matrix protein that is expressed in all-active phases of 
the cell cycle except resting cells.
 
Ki-67 immunoexpression is associated with 
aggressive disease behaviour in penile cancer, however is not found to have any 
prognostic value for cancer-specific survival and overall survival (110). Other factors 
likely involved in penile carcinogenesis include e-cadherin and matrix 
metalloprotease-9, which have been associated with lymph node metastasis and 
disease recurrence in PSCC, respectively (109, 111). (Table 1.5) 
          
                                                                                                          	




Table 1.5 Common Somatic Genetic Alterations in Penile Cancer 
Genetic Change Gene/ Chromosome Frequency References 





13 - 40% 
9 - 29% 
17% 
6 - 19% 
1 - 9% 




(114, 115, 117) 
 






88 - 92% 
46% 
42 - 44% 
17 - 42% 





(88, 104, 107, 119) 













1p13.3 - q44 
3q13.3 - q29 
8q21.2 - q24.3 
88% 
42 - 86% 
42 - 84% 
(97) 
(97, 98) 
(97, 98, 120, 121) 
 
Copy Number Loss 2q33 - q37.3 
3p24.3 - q11.1 
11q12.2 - q25 
 
86% 








                                                                                                          	




1.4 Phosphatidylinositol 3-Kinase (PI3K) Family 
PI3K are a family of lipid kinases that are characterised by their capability to 
phosphorylate inositol phospholipids, thus activating signalling pathways that regulate 
key cellular processes (122, 123). They are divided into three classes according to 
their structural characteristics, substrate specificity and biochemical function (124-
127).  
Briefly, class I PI3Ks are divided in to the subclasses, IA and IB based on their mode 
of regulation. Class IA PI3Ks are heterodimers made up of a single p110 catalytic 
subunit, of which they are three different isoforms (encoded by the genes PIK3CA - 
p110α, PIK3CB - p110β and PIK3CD - p110δ) and a single p85 regulatory subunit. 
There are five regulatory p85 subunit isoforms, which include p85α (and its splice 
variants p55α and p50α, encoded by PIK3R1), p85β (encoded by PIK3R2) and p55γ 
(encoded by PIK3R3). Class IB PI3K is a heterodimer composed of a catalytic subunit 
p110γ (encoded by PIK3CG) coupled with the regulatory subunits p101 (encoded by 
PIK3R5) or p87 (encoded by PIK3R6). The catalytic subunits, p110α and p110β are 
expressed ubiquitously, whereas, p110δ and p110γ is mainly expressed in 
leukocytes. The Class I PI3Ks phosphorylate phosphatidylinositol (4,5) bisphosphate 
(PIP2) into phosphatidylinositol (3,4,5) trisphosphate (PIP3), which leads to various 
diverse functions from cellular survival and proliferation to motility (124, 125).  
Less is known about the class II PI3Ks, which consist of a single catalytic subunit and 
are thought to preferentially phosphorylate phosphatidylinositol (PI) into 
phosphatidylinositol (3) phosphate (PIP). There are three class II PI3Ks isoforms that 
include PI3KC2α, PI3KC2β and PI3KC2γ and are thought to have cellular functions, 
which include glucose metabolism, cellular survival and migration (124, 128). 
The ubiquitously expressed, single class III PI3K, is a heterodimer of the catalytic 
subunit VPS34 and the regulatory subunit VPS15 which phosphorylates PI into PIP 
and is found to have a crucial role in intracellular trafficking and autophagy (125). 
(Figure 1.6) 
                                                                                                          	





Figure 1.6 Different Classes, Subunit Isoforms and Functions of the Phosphatidylinositol 3-Kinase (PI3K) 
Family. Class IA and IB PI3Ks - in vivo, phosphorylate PIP2 into PIP3 with diverse cellular functions, which include 
cell motility, growth, transformation, metabolism and survival. Class IA PI3Ks - have a p110 catalytic subunit isoforms 
(α, β, δ), a helical domain, a membrane-interacting (C2) domain, a RAS-binding domain (RBD) and a p85-binding 
domain (p85-BD). They have multiple heterodimeric regulatory subunit isoforms which have, inter-SH2 (iSH2) domain 
that binds to class IA catalytic subunits, flanked by SH2 domains that bind to phosphorylated YXXM motifs on RTK or 
insulin receptor substrates. The longer isoforms, p85α and p85β, additionally have amino-terminal SH3 and 
breakpoint cluster homology (BH) domains, which are thought to have a negative regulatory effect on the catalytic 
activity of the p110 subunit. Class IB PI3Ks - are heterodimers with a p110γ catalytic subunit and a p101 or p87 
regulatory subunit. The structure of the regulatory subunits p101 and p87 are not fully known, but a carboxy-terminal 
domain (Gβγ binding domain) in p101 has been shown to bind Gβγ, which recruits the p110γ subunit to the plasma 
membrane. Class II PI3Ks - are monomeric and only comprise a catalytic subunit. Their cellular functions include 
glucose transport, endocytosis, cell migration and survival. Three isoforms exist for this class, which are PI3K-C2α, 
PI3K-C2β and PI3K-C2γ. Class III PI3K - consists of a vacuolar protein sorting 34 (VPS34) subunit, which only has a 
catalytic, C2 and helical domain. This subunit forms a heterodimer with VPS15 that consists of a catalytic domain, a 
HEAT domain and WD40 repeats of which the latter two likely mediate protein-protein interaction. They have crucial 
roles in phagocytosis, autophagy and endosomal trafficking. Adapted from Thorpe LM et al. (125) 
 
The Class IA PI3Ks are well known to be involved in oncogenesis and have been 
implicated in several human cancers. Of the three class IA PI3K catalytic isoforms, 
the p110α catalytic subunit is the most frequently found isoform to be altered via 
mutations, amplifications and/or copy number gain in human cancer (124, 125).  
                                                                                                          	




1.4.1  Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit  
  Alpha (PIK3CA) Activation, Downstream Effects and Genetic   
  Alterations 
The PIK3CA oncogene is located on chromosome 3q26.3 and encodes the p110α 
protein. This protein forms a heterodimer with the p85 regulatory subunit to create the 
PI3Kα lipid kinase which is expressed ubiquitously (124). The p110α protein 
phosphorylates its target lipid substrate, PIP2 to PIP3 and the p85 regulatory subunit 
negatively regulates the catalytic activity of p110α via the helical domain and 
mediates receptor binding, activation and membrane localisation of PI3Kα enzyme 
(124, 127). (Figure 1.7)  
 
 
Figure 1.7 Schemata of p110α Protein Structure. The p110α protein is encoded by the PIK3CA oncogene. This 
protein is made up of 5 domains: the p85-binding domain, the RAS-binding domain, the membrane interacting C2 
domain, the helical domain and the catalytic kinase domain. Adapted from Vanhaesebroeck et al. (128) 
 
The PI3Kα complex resides in the cytoplasm in its inactive form. Activation occurs 
directly or indirectly via growth factor RTK (129). In direct activation, ligand-mediated 
activation of the kinase activity and trans-phosphorylation of the RTK cytoplasmic tail 
is followed by PI3Kα recruitment to the membrane via interaction of the SH2 domain 
of the p85 subunit with tyrosine phosphate motifs on activated receptors directly (e.g. 
EGFR) or to adaptor proteins associated with the receptors (e.g. insulin receptor 
substrate 1, IRS1). RTKs can also activate PI3Kα, indirectly though RAS, which can 
bind and activate the p110α subunit. Both methods lead to a conformational change 
in PI3Kα, which relieves the p85 subunit inhibitory effect on the p110α subunit, 
resulting in membrane localisation and stabilisation of PI3Kα (122, 123, 129). (Figure 
1.8)  
                                                                                                          	





Figure 1.8 Modes of PI3K Activation. Ligand-mediated activation of the RTKs is followed by PI3K recruitment to the 
membrane via interaction of the SH2 domain of the p85 subunit with tyrosine phosphate motifs on activated receptors 
directly or to adaptor proteins associated with the receptors such as IRS1/2. These SH2–phosphotyrosine interactions 
bring PI3K in close proximity to its substrate at the plasma membrane and relieve the inhibitory action of p85 on the 
p110 catalytic subunit, which converts PIP2 into PIP3. RTKs can also activate PI3K, indirectly though RAS, which can 
bind, stabilise and activate the p110 subunit. This occurs by recruitment of the adaptor proteins SHC, GRB2 and 
GAB2 to activated RTKs. Vivanco et al. (129) 
 
At the plasma membrane, PI3Kα phosphorylates its substrate PIP2 to PIP3. This lipid 
product acts as a second messenger, recruiting a subset of signaling proteins with 
pleckstrin homology domains such as PDK1 and AKT to the membrane leading to 
activation of multiple downstream signaling pathways. The phosphatase and tensin 
homolog (PTEN), a lipid phosphoinositide 3-phosphatase, acts to dephosphorylate 
PIP3 to PIP2, to inactivate PI3Kα signalling (129, 130). 
The serine/threonine kinase, AKT, is the foremost pleckstrin homolog domain 
containing protein, activated by PIP3. Recruitment to the membrane by PIP3, results in 
a conformational change in AKT, which exposes two critical amino acid residues for 
phosphorylation. Phosphorylation at threonine 308 by PDK1 is necessary and 
sufficient for AKT activation; however, an additional phosphorylation at serine 473 by 
PDK2 (currently thought to be mTORC2; the mTOR/rictor complex) is required for 
maximal activation of AKT. Activated AKT phosphorylates numerous protein targets 
and regulates a wide range of key cellular process involved in protein synthesis, cell 
survival, proliferation, growth, angiogenesis and metabolism. 
                                                                                                          	




One of the primary targets of AKT is mTORC1 (mTOR/raptor complex), which is a 
central regulator of cellular metabolism and biosynthesis and essential for the 
oncogenicity of PI3Kα and AKT (123, 124, 131, 132). Aoki et al. demonstrated that 
mTOR inhibition by the antibiotic rapamycin strongly and specifically reduced PI3K- 
and AKT-induced cellular transformation of chicken embryo fibroblasts (133).  
Additionally PI3Kα and PIP3 have also been shown to regulate the activity of other 
downstream effector molecules through poorly characterized mechanisms. These 
include RAC1 and serum and glucocorticoid-inducible kinase (SGK) of which, their 
activities are thought to involve a role in cell cytoskeleton rearrangement and survival, 
respectively (134, 135). (Figure 1.9) 
 
 
Figure 1.9 Class IA PI3K Signalling Pathways. Activation of PI3Ks leads to phosphorylation of the p85 subunit of 
the PI3K heterodimer, which subsequently activates the catalytic subunit, p110. This phosphorylated heterodimer 
catalyses the conversion of PIP2 into PIP3. This step is negatively regulated by PTEN, which dephosphorylates PIP3 
into PIP2. PIP3 generation on the inner leaflet of the plasma membrane recruits AKT by direct interaction with their 
pleckstrin homology domain. At the membrane PDK-1 phosphorylates AKT at threonine T308 and PDK-2 (mTOR2) 
phosphorylates AKT at serine residue S473, for maximal AKT activation. Activated AKT then mediates the activation 
or inhibition of multiple targets, such as mTOR, which results in cellular growth, survival and proliferation. In addition, 
PI3K have also been shown to regulate the activity of other cellular targets, in an AKT-independent manner such as 
SGK and the small GTP-binding proteins RAC1 and CDC42. The activity of which also leads to cellular survival, 
transformation and motility. Adapted from Porta et al. (123) 
                                                                                                          	




Somatic mutations in PIK3CA occur in up to 30% of common epithelial cancers, such 
as breast, endometrial and colon cancers (125). Missense mutations occur in all 
domains of p110α, and 80% of all mutations in the PIK3CA gene occur in two ‘hot 
spot’ regions, the most common being E542K and E545K in the helical domain and 
H1047R in the kinase domain. The two helical domain mutations reduce inhibition of 
p110α by the p85 regulatory subunit and the H1047R kinase domain mutation 
induces a conformational change in the activation loop leading to less upstream 
signal transduction dependent activation and thus access to its lipid substrate in the 
membranes (130, 136). Other rare cancer-specific mutations are also seen in the 
PIK3CA gene such as C420R which occurs in the C2 domain and increases the basic 
positive surface charge of the domain and hence likely increases p110α recruitment 
to the cell membrane (137).  
In vitro studies and genetically engineered mouse models have confirmed that these 
PIK3CA hotspot mutations lead to cellular transformation, tumour initiation and 
progression by the constitutive activation of p110α (128, 138, 139). Rare PIK3CA 
mutations also have similar transformative capabilities, however not to the same 
extent as the hotspot mutations and this superior activity of the hotspot mutants likely 
explains their higher occurrence in cancer (137). 
PIK3CA gene amplification and copy number gain are also common in cancer (128). 
In cervical and ovarian cancer cell lines, increased PIK3CA gene copy number is 
associated with increased p110α transcription, translation and total PI3Kα activity. 
This overexpression of a structurally normal PI3Kα protein likely contributes to 
malignant transformation via activation of AKT-dependent and AKT-independent 
downstream signaling pathways (129, 140, 141). 
1.4.2 PI3K-AKT-mTOR Pathway in Penile Carcinogenesis 
The deregulated PI3K-AKT-mTOR pathway plays a pivotal role in many human 
cancers leading to cellular proliferation, survival and angiogenesis. In addition, it 
provides an attractive target for cancer therapeutics and biomarker identification 
(142).  
Multiples studies have taken place looking into PI3K-AKT-mTOR pathway in PSCC. 
Stankiewicz et al. (23) found activated EGFR (phospho-EGFR), HER3 and HER4, all 
of which are transmembrane RTKs which stimulate PI3K-AKT-mTOR signalling, are 
overexpressed in a cohort of 148 PSCC cases. They also reported HPV negative 
                                                                                                          	




tumours expressed significantly more phospho-EGFR than HPV positive tumours and 
this expression correlated with activated AKT (phospho-AKT, p=0.002). Conversely, 
HER3 expression was significantly more common in HPV positive cases, which 
correlated with AKT1 protein expression. Limited data on targeted inhibition of EGFR 
by anti-EGFR antibodies such as panitumumab have shown promising results in 
patients with advanced penile cancers (73). 
The PIK3CA oncogene was found to be mutated in 8/28 (29%) penile cancer cases 
by Andersson et al. (114) and Ferrandiz-Pulido et al. (115) more recently found a 
lower prevalence of PIK3CA mutations in 6/65 (9%) PSCC cases. The PI3K pathway 
can also be activated by the RAS oncogene. Activating mutations in RAS are 
common in cancer and have been found in 1-18% of penile cancers (114, 115, 117).  
On the other hand, decreased immunoexpression of PTEN, a tumour suppressor 
gene and repressor of the PI3K pathway, is a common event in PSCC present in 62-
75% of cases (23, 117). However, loss of PTEN protein is not due to genetic events 
such as DNA copy number loss or silencing mutations and does not correlate with 
activated phospho-AKT immunoexpression as described by Stankiewicz et al. (23). 
This may mean that epigenetic mechanisms such as DNA methylation could be 
attributed to this reduction in PTEN immunoexpression. Or alternatively, other factors 
may have a greater impact on the activity of the PI3K-AKT-mTOR pathway in PSCC 
than PTEN such as PIK3CA for example (23, 114, 143). 
Few studies, have investigated the downstream components of the PI3K-AKT-mTOR 
pathway in penile cancer. Ferrandiz-Pulido et al. (144) in 67 PSCC cases found 
phospho-mTOR (activated mTOR) and phospho-elF4E (a downstream effector 
protein of mTOR) immunoexpression was significantly increased in PSCC compared 
to adjacent normal tissues and associated with lymph node metastasis (p=0.05 and 
p=0.006, respectively). Secondly, Chaux et al. (143) found that in 112 PSCC cases 
phospho-S6 (a downstream effector protein of mTOR) immunoexpression, was 
significantly higher in low-grade tumours (p=0.001). This suggests that mTOR plays a 
role both in early and late stage penile carcinogenesis and possibly represents an 
attractive therapeutic target.  
HrHPV has also been shown to utilise the PI3K-AKT-mTOR pathway as it develops 
and establishes a malignant phenotype. Examples include the E5 viral oncoprotein, 
which is expressed in the early stages of carcinogenesis and induces the expression 
of VEGF through activation of EGFR and phosphorylation of AKT and MAPK (145). 
                                                                                                          	




HrHPV oncoprotein E6 has been shown to reduce PTEN and increase PIK3CA gene 
transcription levels by degradation of hDlg and p53 proteins, respectively (146, 147). 
And finally, the E7 oncoprotein has been shown to activate the PI3K-AKT pathway by 
inhibition of the phosphatase, PP2A, which acts to suppress AKT (148). 
1.4.3 PIK3CA Copy Number Gain in Other HPV Induced Squamous Cell  
  Carcinomas and Activation of the PI3K-AKT-mTOR pathway 
There are distinct similarities in the genetic alterations between PSCC and other HPV 
induced squamous cell carcinomas (HISCCs). One such shared feature is the 
amplification or copy number gain of chromosome arm 3q, including the 3q26.3 
region, which harbours PIK3CA. This has been shown to be one of the most 
consistent aberrations in cervical (140), head and neck (149) and oesophageal 
cancers (150).  
Akagi et al. (151) found 12/45 (26.7%) tumours with PIK3CA amplification in 
oesophageal squamous cell carcinoma (OSCC) and Fenic et al. (152) found 16/33 
(48.5%) with PIK3CA copy number gain in head and neck squamous cell carcinoma 
(HNSCC). Recent work by La-Touche et al. (97) found copy number gains in 55/64 
cases (86%) within the 3p12.3-q29 loci, similar to Busso-Lopes et al. (98) in PSCC. 
Within this chromosomal region resides the PIK3CA oncogene, at the 3q26.3 locus, 
which was found to harbour a high prevalence of copy number gains, 79/258 (31%) in 
PSCC (97). 
These genetic alterations have been shown to increase the activity of the PI3K-AKT-
mTOR pathway in HISCCs. For example, Bertelsen et al. (153) found that PIK3CA 
amplification was significantly associated with increased immunoexpression of 
activated AKT (phospho-AKT (Ser473)) in cervical squamous cell carcinoma (CSCC) 
(p=0.006). And Clark et al. (154) identified that HNSCC cases had significantly higher 
levels of activated mTOR (phospho-mTOR (Ser2448)) than normal uvula cases via 
western blot (p=0.026) and immunohistochemistry (IHC) (81.9% vs. 0%; p<0.001).  
Currently, three therapeutic agents targeting the PI3K-AKT-mTOR pathway have 
been approved for clinical use in treating various different cancers. These include the 
mTOR inhibitors, everolimus and temsirolimus, which have both been licenced for 
use in renal cell carcinoma among other tumours (123). And lastly, idelalisib, a PI3K 
p110δ inhibitor, has been approved for the treatment of haematological malignancies 
                                                                                                          	




such as chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma (155, 156). In 
addition, a vast number of other biological therapies targeting the PI3K-AKT-mTOR 
pathway are currently in pre-clinical studies and clinical trials in multiple advanced 
solid tumours including HISCCs (136) such as cervical (157, 158) and HNSCC (159, 
160). Preclinical models have demonstrated some evidence of the predictive 
capabilities of PIK3CA mutations and activated AKT and mTOR proteins assessed by 
IHC in predicting treatment sensitivity to therapies targeting the PI3K-AKT-mTOR 
pathway, but have not been validated in the clinical setting (161, 162). Potentially, 
PIK3CA copy number gain could prove a useful marker for the activation and thus, 
use of biological therapies to target the PI3K-AKT-mTOR pathway in PSCC. 
 
1.5 Aim  
Based on our previous findings (97), we hypothesize that PIK3CA copy number gain 
is an oncogenic driver of penile carcinogenesis via activation of the PI3K-AKT-mTOR 
pathway and has the potential to be used as a marker of this pathways activation that 
presents an opportunity for targeted therapeutics in PSCC. 
 
The aims of my project are: 
1. To evaluate the prevalence of PIK3CA copy number gain in evolving disease 
stages of PSCC with fluorescence in-situ hybridisation (FISH) and correlate this 
with PIK3CA RNA and PI3Kα protein expression. 
 
2. To assess the activity of the PI3K-AKT-mTOR pathway in PSCC using 
western blot and IHC and correlate to PIK3CA copy number status. 
 
3. To evaluate the potential use of PIK3CA copy number status as a marker of 
lymph node metastasis and prognostication in PSCC via correlation with 
histopathological parameters and clinical outcome data. 
                                                                                                          	





METHODS AND MATERIALS 
 
2.1 Primary Tissue Specimen 
2.1.1 Fresh Frozen Clinical Specimen 
Twenty-four fresh frozen primary PSCC specimens with corresponding normal 
adjacent penile epithelium samples available for 15 of these specimen, were obtained 
under ethical approval from St George’s Hospital in London. (Table 2.1 and Figure 
2.1A) 
 
Table 2.1 Fresh Frozen Primary PSCC Cohort - Patient and Tumour 
Characteristics 
Patient and Tumour Characteristics 




66 (35 - 86) 





 3 (12%) 
 9 (38%) 
 9 (38%) 
 3 (12%) 
Nodal Stage  
NX   4 (16%) 
N0   9 (38%) 
N1 1 (4%) 
N2 1 (4%) 
N3   9 (38%) 
                                                                                                          	




2.1.2 Formalin-Fixed Paraffin Embedded (FFPE) Clinical Specimen 
Tissue microarray (TMA) blocks containing FFPE penile tissue cores from 244 
primary PSCC, 15 normal penile epithelium and 58 PeIN samples were available in 
our laboratory for FISH and IHC analysis. Tissue samples for TMAs preparation were 
obtained under ethical approval from St George’s Hospital in London (Table 2.2 and 
Figure 2.1A&B) 
 
Table 2.2 FFPE Primary PSCC Cohort - Patient and Tumour Characteristics 
Patient and Tumour Characteristics 




65 (28 - 91) 







 80 (33%) 
112 (46%) 
  42 (17%) 
  8 (3%) 
 Nodal Stage  
NX   26 (11%) 
N0 143 (57%) 
N1   31 (13%) 
N2 21 (9%) 





                                                                                                          	




Additionally, TMA blocks, containing 27 FFPE advanced primary PSCC were 
obtained under ethical approval from the national Phase II Trial of docetaxel, cisplatin 
and 5-fluorouracil (TPF) chemotherapy in penile cancer (67). These 27 FFPE 
samples of advanced primary PSCC came from patients who had developed 
aggressive locally advanced or metastatic disease at presentation. (Table 2.3 and 
Figure 2.1A&B) 
 
Table 2.3 FFPE Advanced Primary PSCC Cohort - Patient and Tumour 
Characteristics 
Patient and Tumour Characteristics 




61 (49 - 72) 





  9 (33%) 
  5 (19%) 
  7 (26%) 
  6 (22%) 
 Nodal Stage  
N1   5 (19%) 








 8 (30%) 
